{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:37:53Z","timestamp":1789706273952,"version":"4.0.1"},"reference-count":219,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T00:00:00Z","timestamp":1522713600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["16046"],"award-info":[{"award-number":["16046"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008414","name":"Associazione Sammarinese per la Lotta Contro le Leucemie e le Emopatie Maligne","doi-asserted-by":"publisher","award":["CFR 2015-2016"],"award-info":[{"award-number":["CFR 2015-2016"]}],"id":[{"id":"10.13039\/501100008414","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002410","name":"Universit\u00e0 e Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002410","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2018.00091","type":"journal-article","created":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T04:19:10Z","timestamp":1522729150000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":57,"title":["New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma"],"prefix":"10.3389","volume":"8","author":[{"given":"Marika","family":"Rossini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Bononi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Clementz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro G.","family":"Tognon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,4,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/ajim.20209","article-title":"The global burden of disease due to occupational carcinogens","volume":"48","author":"Driscoll","year":"2005","journal-title":"Am J Ind Med"},{"key":"B2","first-page":"919","article-title":"Malignant mesothelioma of the pleural space","volume":"13","author":"Grondin","year":"1999","journal-title":"Oncology (Williston Park)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1001\/jamaoncol.2016.5487","article-title":"Association of asbestos exposure with malignant mesothelioma incidence in Eastern China","volume":"3","author":"Mao","year":"2017","journal-title":"JAMA Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.jtho.2016.04.028","article-title":"Consensus report of the 2015 Weinman international conference on mesothelioma","volume":"11","author":"Carbone","year":"2016","journal-title":"J Thorac Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S1470-2045(13)70257-2","article-title":"Asbestos is not just asbestos: an unrecognised health hazard","volume":"14","author":"Baumann","year":"2013","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/j.ajpath.2013.07.029","article-title":"Continuous exposure to chrysotile asbestos can cause transformation of human mesothelial cells via HMGB1 and TNF-alpha signaling","volume":"183","author":"Qi","year":"2013","journal-title":"Am J Pathol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1097\/JTO.0000000000000506","article-title":"The presence of asbestos in the natural environment is likely related to mesothelioma in young individuals and women from Southern Nevada","volume":"10","author":"Baumann","year":"2015","journal-title":"J Thorac Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"259","DOI":"10.21037\/tlcr.2017.05.06","article-title":"Diagnostic and prognostic biomarkers for malignant mesothelioma: an update","volume":"6","author":"Chen","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1053\/j.semdp.2006.08.002","article-title":"The pathogenesis of mesothelioma","volume":"23","author":"Carbone","year":"2006","journal-title":"Semin Diagn Pathol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/carcin\/bgu227","article-title":"Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival","volume":"36","author":"Baumann","year":"2015","journal-title":"Carcinogenesis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s002680020021","article-title":"Treatment of malignant mesothelioma","volume":"25","author":"Jaklitsch","year":"2001","journal-title":"World J Surg"},{"key":"B12","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1158\/1940-6207.CAPR-15-0347","article-title":"Inflammation-related IL1beta\/IL1R signaling promotes the development of asbestos-induced malignant mesothelioma","volume":"9","author":"Kadariya","year":"2016","journal-title":"Cancer Prev Res (Phila)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"13618","DOI":"10.1073\/pnas.1105887108","article-title":"Erionite exposure in North Dakota and Turkish villages with mesothelioma","volume":"108","author":"Carbone","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B14","doi-asserted-by":"publisher","first-page":"10397","DOI":"10.1073\/pnas.0604008103","article-title":"TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis","volume":"103","author":"Yang","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B15","doi-asserted-by":"publisher","first-page":"5942","DOI":"10.1158\/1078-0432.CCR-07-0536","article-title":"Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma","volume":"13","author":"Sartore-Bianchi","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"248","DOI":"10.21037\/tlcr.2017.04.12","article-title":"In vitro experimental models of mesothelioma revisited","volume":"6","author":"Singh","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"238","DOI":"10.21037\/atm.2017.04.29","article-title":"Mesothelioma: recent highlights","volume":"5","author":"Carbone","year":"2017","journal-title":"Ann Transl Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1158\/1055-9965.EPI-04-0903","article-title":"A molecular epidemiology case control study on pleural malignant mesothelioma","volume":"14","author":"Bolognesi","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/01913120252959227","article-title":"Malignant mesothelioma and occupational exposure to asbestos: a clinicopathological correlation of 1445 cases","volume":"26","author":"Roggli","year":"2002","journal-title":"Ultrastruct Pathol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"234","DOI":"10.21037\/atm.2017.03.74","article-title":"Environmental asbestos exposure and risk of mesothelioma","volume":"5","author":"Noonan","year":"2017","journal-title":"Ann Transl Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1158\/0008-5472.CAN-04-2219","article-title":"SV40 enhances the risk of malignant mesothelioma among people exposed to asbestos: a molecular epidemiologic case-control study","volume":"65","author":"Cristaudo","year":"2005","journal-title":"Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"9488","DOI":"10.1158\/0008-5472.CAN-08-2332","article-title":"A novel mechanism of late gene silencing drives SV40 transformation of human mesothelial cells","volume":"68","author":"Carbone","year":"2008","journal-title":"Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virol.2003.09.004","article-title":"Simian virus 40 infection in humans and association with human diseases: results and hypotheses","volume":"318","author":"Barbanti-Brodano","year":"2004","journal-title":"Virology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3816\/CLC.2003.n.031","article-title":"Molecular pathogenesis of malignant mesothelioma and its relationship to simian virus 40","volume":"5","author":"Gazdar","year":"2003","journal-title":"Clin Lung Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"14128","DOI":"10.1073\/pnas.0604544103","article-title":"Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters","volume":"103","author":"Kroczynska","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B26","first-page":"875","article-title":"Simian virus 40: the link with human malignant mesothelioma is well established","volume":"20","author":"Carbone","year":"2000","journal-title":"Anticancer Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"18066","DOI":"10.1073\/pnas.1213238109","article-title":"High prevalence of serum antibodies reacting with simian virus 40 capsid protein mimotopes in patients affected by malignant pleural mesothelioma","volume":"109","author":"Mazzoni","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B28","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1158\/0008-5472.CAN-15-0295","article-title":"Germline BAP1 mutational landscape of asbestos-exposed malignant mesothelioma patients with family history of cancer","volume":"76","author":"Ohar","year":"2016","journal-title":"Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1007\/s10552-009-9357-4","article-title":"Ionizing radiation: a risk factor for mesothelioma","volume":"20","author":"Goodman","year":"2009","journal-title":"Cancer Causes Control"},{"key":"B30","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/jcp.22724","article-title":"Malignant mesothelioma: facts, myths, and hypotheses","volume":"227","author":"Carbone","year":"2012","journal-title":"J Cell Physiol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1053\/sonc.2002.30227","article-title":"The pathogenesis of mesothelioma","volume":"29","author":"Carbone","year":"2002","journal-title":"Semin Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3978\/j.issn.2225-319X.2012.11.04","article-title":"Malignant pleural mesothelioma: an epidemiological perspective","volume":"1","author":"Robinson","year":"2012","journal-title":"Ann Cardiothorac Surg"},{"key":"B33","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s11864-008-0067-z","article-title":"Mesothelioma epidemiology, carcinogenesis, and pathogenesis","volume":"9","author":"Yang","year":"2008","journal-title":"Curr Treat Options Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1043\/1543-2165-133.8.1317","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group","volume":"133","author":"Husain","year":"2009","journal-title":"Arch Pathol Lab Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"10","DOI":"10.5858\/arpa.2017-0124-RA","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma: 2017 update of the consensus statement from the International Mesothelioma Interest Group","volume":"142","author":"Husain","year":"2017","journal-title":"Arch Pathol Lab Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s00508-016-1080-z","article-title":"Management of malignant pleural mesothelioma \u2013 part 1: epidemiology, diagnosis, and staging: consensus of the Austrian Mesothelioma Interest Group (AMIG)","volume":"128","author":"Geltner","year":"2016","journal-title":"Wien Klin Wochenschr"},{"key":"B37","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.jtho.2015.12.108","article-title":"A novel clinical prediction model for prognosis in malignant pleural mesothelioma using decision tree analysis","volume":"11","author":"Brims","year":"2016","journal-title":"J Thorac Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jtho.2015.10.003","article-title":"Contemporary analysis of prognostic factors in patients with unresectable malignant pleural mesothelioma","volume":"11","author":"Bille","year":"2016","journal-title":"J Thorac Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1016\/j.celrep.2016.07.082","article-title":"PML at mitochondria-associated membranes is critical for the repression of autophagy and cancer development","volume":"16","author":"Missiroli","year":"2016","journal-title":"Cell Rep"},{"key":"B40","doi-asserted-by":"publisher","first-page":"49664","DOI":"10.18632\/oncotarget.10430","article-title":"P2X7 targeting inhibits growth of human mesothelioma","volume":"7","author":"Amoroso","year":"2016","journal-title":"Oncotarget"},{"key":"B41","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/nature22798","article-title":"BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation","volume":"546","author":"Bononi","year":"2017","journal-title":"Nature"},{"key":"B42","doi-asserted-by":"publisher","first-page":"23427","DOI":"10.18632\/oncotarget.4370","article-title":"The endoplasmic reticulum mitochondrial calcium cross talk is downregulated in malignant pleural mesothelioma cells and plays a critical role in apoptosis inhibition","volume":"6","author":"Patergnani","year":"2015","journal-title":"Oncotarget"},{"key":"B43","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1164\/rccm.201006-0980OC","article-title":"A(3) receptors are overexpressed in pleura from patients with mesothelioma and reduce cell growth via Akt\/nuclear factor-kappaB pathway","volume":"183","author":"Varani","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1097\/JTO.0b013e31820db125","article-title":"MicroRNAs dysregulation in human malignant pleural mesothelioma","volume":"6","author":"Balatti","year":"2011","journal-title":"J Thorac Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"82700","DOI":"10.18632\/oncotarget.12408","article-title":"Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers","volume":"7","author":"Bononi","year":"2016","journal-title":"Oncotarget"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat Genet"},{"key":"B47","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/1479-5876-10-179","article-title":"BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs","volume":"10","author":"Carbone","year":"2012","journal-title":"J Transl Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrc3459","article-title":"BAP1 and cancer","volume":"13","author":"Carbone","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"B49","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1073\/pnas.1309085110","article-title":"Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair","volume":"111","author":"Yu","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B50","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.celrep.2016.05.096","article-title":"NeuCode proteomics reveals Bap1 regulation of metabolism","volume":"16","author":"Baughman","year":"2016","journal-title":"Cell Rep"},{"key":"B51","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1073\/pnas.1619588114","article-title":"BAP1 inhibits the ER stress gene regulatory network and modulates metabolic stress response","volume":"114","author":"Dai","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1038\/cdd.2017.95","article-title":"Germline BAP1 mutations induce a Warburg effect","volume":"24","author":"Bononi","year":"2017","journal-title":"Cell Death Differ"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1126\/science.1194472","article-title":"Frequent mutation of BAP1 in metastasizing uveal melanomas","volume":"330","author":"Harbour","year":"2010","journal-title":"Science"},{"key":"B54","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","article-title":"High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"J Thorac Oncol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/j.1349-7006.2012.02223.x","article-title":"Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma","volume":"103","author":"Yoshikawa","year":"2012","journal-title":"Cancer Sci"},{"key":"B56","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1586\/17476348.2015.1081066","article-title":"Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies","volume":"9","author":"Bononi","year":"2015","journal-title":"Expert Rev Respir Med"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/j.humpath.2015.06.024","article-title":"BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma","volume":"46","author":"McGregor","year":"2015","journal-title":"Hum Pathol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/his.13123","article-title":"Diagnostic utility of BAP1 and EZH2 expression in malignant mesothelioma","volume":"70","author":"Shinozaki-Ushiku","year":"2017","journal-title":"Histopathology"},{"key":"B59","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1016\/j.jtho.2016.06.020","article-title":"BRCA1-associated protein 1 (BAP1) immunohistochemical expression as a diagnostic tool in malignant pleural mesothelioma classification: a large retrospective study","volume":"11","author":"Righi","year":"2016","journal-title":"J Thorac Oncol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"13432","DOI":"10.1073\/pnas.1612074113","article-title":"High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma","volume":"113","author":"Yoshikawa","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B61","doi-asserted-by":"publisher","first-page":"e1005633","DOI":"10.1371\/journal.pgen.1005633","article-title":"Combined genetic and genealogic studies uncover a large BAP1 cancer syndrome kindred tracing back nine generations to a common ancestor from the 1700s","volume":"11","author":"Carbone","year":"2015","journal-title":"PLoS Genet"},{"key":"B62","doi-asserted-by":"publisher","first-page":"4388","DOI":"10.1158\/0008-5472.CAN-14-1328","article-title":"Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma","volume":"74","author":"Xu","year":"2014","journal-title":"Cancer Res"},{"key":"B63","first-page":"5547","article-title":"p16 alterations and deletion mapping of 9p21\u2013p22 in malignant mesothelioma","volume":"54","author":"Cheng","year":"1994","journal-title":"Cancer Res"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.4161\/cc.4.12.2300","article-title":"Similar tumor suppressor gene alteration profiles in asbestos-induced murine and human mesothelioma","volume":"4","author":"Lecomte","year":"2005","journal-title":"Cell Cycle"},{"key":"B65","doi-asserted-by":"publisher","first-page":"e18828","DOI":"10.1371\/journal.pone.0018828","article-title":"Losses of both products of the Cdkn2a\/Arf locus contribute to asbestos-induced mesothelioma development and cooperate to accelerate tumorigenesis","volume":"6","author":"Altomare","year":"2011","journal-title":"PLoS One"},{"key":"B66","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1186\/s12885-017-3382-6","article-title":"Whole exome sequencing of an asbestos-induced wild-type murine model of malignant mesothelioma","volume":"17","author":"Sneddon","year":"2017","journal-title":"BMC Cancer"},{"key":"B67","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1093\/mutage\/get008","article-title":"Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma","volume":"28","author":"Andujar","year":"2013","journal-title":"Mutagenesis"},{"key":"B68","first-page":"1","article-title":"Neurofibromatosis type 2 protein, NF2: an uncoventional cell cycle regulator","volume":"33","author":"Beltrami","year":"2013","journal-title":"Anticancer Res"},{"key":"B69","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3892\/or.14.3.743","article-title":"Mutational analysis of 9 different tumour-associated genes in human malignant mesothelioma cell lines","volume":"14","author":"Kumar","year":"2005","journal-title":"Oncol Rep"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1002\/cncr.22552","article-title":"Update on the molecular biology of malignant mesothelioma","volume":"109","author":"Lee","year":"2007","journal-title":"Cancer"},{"key":"B71","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/nm0897-908","article-title":"Simian virus-40 large-T antigen binds p53 in human mesotheliomas","volume":"3","author":"Carbone","year":"1997","journal-title":"Nat Med"},{"key":"B72","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nm0897-913","article-title":"The retinoblastoma gene family pRb\/p105, p107, pRb2\/p130 and simian virus-40 large T-antigen in human mesotheliomas","volume":"3","author":"De Luca","year":"1997","journal-title":"Nat Med"},{"key":"B73","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/ijc.20150","article-title":"SV40 and human cancers","volume":"110","author":"Tognon","year":"2004","journal-title":"Int J Cancer"},{"key":"B74","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1006\/scbi.2000.0347","article-title":"SV40 and the pathogenesis of mesothelioma","volume":"11","author":"Rizzo","year":"2001","journal-title":"Semin Cancer Biol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coph.2016.03.002","article-title":"Alterations of calcium homeostasis in cancer cells","volume":"29","author":"Marchi","year":"2016","journal-title":"Curr Opin Pharmacol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.bbrc.2008.07.153","article-title":"Akt kinase reducing endoplasmic reticulum Ca2+ release protects cells from Ca2+-dependent apoptotic stimuli","volume":"375","author":"Marchi","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"B77","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1093\/emboj\/20.11.2690","article-title":"The Ca2+ concentration of the endoplasmic reticulum is a key determinant of ceramide-induced apoptosis: significance for the molecular mechanism of Bcl-2 action","volume":"20","author":"Pinton","year":"2001","journal-title":"EMBO J"},{"key":"B78","doi-asserted-by":"publisher","first-page":"e1167","DOI":"10.1038\/cddis.2014.136","article-title":"Autocrine CSF-1R signaling drives mesothelioma chemoresistance via AKT activation","volume":"5","author":"Cioce","year":"2014","journal-title":"Cell Death Dis"},{"key":"B79","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.4161\/cc.25972","article-title":"Protect and serve: Bcl-2 proteins as guardians and rulers of cancer cell survival","volume":"12","author":"Braun","year":"2013","journal-title":"Cell Cycle"},{"key":"B80","doi-asserted-by":"publisher","first-page":"6080","DOI":"10.1038\/sj.onc.1208744","article-title":"Human and mouse mesotheliomas exhibit elevated AKT\/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth","volume":"24","author":"Altomare","year":"2005","journal-title":"Oncogene"},{"key":"B81","doi-asserted-by":"publisher","first-page":"e36856","DOI":"10.1371\/journal.pone.0036856","article-title":"Perifosine as a potential novel anti-cancer agent inhibits EGFR\/MET-AKT axis in malignant pleural mesothelioma","volume":"7","author":"Pinton","year":"2012","journal-title":"PLoS One"},{"key":"B82","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1038\/bjc.2014.220","article-title":"Multipoint targeting of the PI3K\/mTOR pathway in mesothelioma","volume":"110","author":"Zhou","year":"2014","journal-title":"Br J Cancer"},{"key":"B83","first-page":"2958","article-title":"A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor","volume":"7","author":"Ciardiello","year":"2001","journal-title":"Clin Cancer Res"},{"key":"B84","first-page":"5242","article-title":"Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma","volume":"62","author":"Janne","year":"2002","journal-title":"Cancer Res"},{"key":"B85","first-page":"203","article-title":"Combinational therapy of crizotinib and afatinib for malignant pleural mesothelioma","volume":"7","author":"Huang","year":"2017","journal-title":"Am J Cancer Res"},{"key":"B86","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1080\/08958378.2000.11463242","article-title":"Cell signaling in mesothelial cells by asbestos: evidence for the involvement of oxidative stress in the regulation of the epidermal growth factor receptor","volume":"12","author":"Faux","year":"2000","journal-title":"Inhal Toxicol"},{"key":"B87","first-page":"5334","article-title":"Asbestos causes stimulation of the extracellular signal-regulated kinase 1 mitogen-activated protein kinase cascade after phosphorylation of the epidermal growth factor receptor","volume":"56","author":"Zanella","year":"1996","journal-title":"Cancer Res"},{"key":"B88","first-page":"4833","article-title":"Expression of vascular endothelial growth factor in malignant mesothelioma","volume":"26","author":"Aoe","year":"2006","journal-title":"Anticancer Res"},{"key":"B89","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/path.824","article-title":"Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma","volume":"193","author":"Strizzi","year":"2001","journal-title":"J Pathol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/sj.bjc.6690650","article-title":"VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours","volume":"81","author":"Ohta","year":"1999","journal-title":"Br J Cancer"},{"key":"B91","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1158\/1078-0432.CCR-11-2259","article-title":"Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma","volume":"18","author":"Carbone","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B92","doi-asserted-by":"publisher","first-page":"22649","DOI":"10.18632\/oncotarget.15152","article-title":"HMGB1 targeting by ethyl pyruvate suppresses malignant phenotype of human mesothelioma","volume":"8","author":"Pellegrini","year":"2017","journal-title":"Oncotarget"},{"key":"B93","doi-asserted-by":"publisher","first-page":"3290","DOI":"10.1158\/0008-5472.CAN-11-3481","article-title":"Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma","volume":"72","author":"Jube","year":"2012","journal-title":"Cancer Res"},{"key":"B94","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1158\/1078-0432.CCR-15-1130","article-title":"HMGB1 and its hyperacetylated isoform are sensitive and specific serum biomarkers to detect asbestos exposure and to identify mesothelioma patients","volume":"22","author":"Napolitano","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B95","doi-asserted-by":"publisher","first-page":"e104848","DOI":"10.1371\/journal.pone.0104848","article-title":"Increased levels of C-C chemokine RANTES in asbestos exposed workers and in malignant mesothelioma patients from an hyperendemic area","volume":"9","author":"Comar","year":"2014","journal-title":"PLoS One"},{"key":"B96","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s12199-013-0333-y","article-title":"Altered functions of alveolar macrophages and NK cells involved in asbestos-related diseases","volume":"18","author":"Nishimura","year":"2013","journal-title":"Environ Health Prev Med"},{"key":"B97","doi-asserted-by":"publisher","first-page":"238431","DOI":"10.1155\/2015\/238431","article-title":"Functional alteration of natural killer cells and cytotoxic T lymphocytes upon asbestos exposure and in malignant mesothelioma patients","volume":"2015","author":"Nishimura","year":"2015","journal-title":"Biomed Res Int"},{"key":"B98","doi-asserted-by":"publisher","first-page":"9678","DOI":"10.1158\/0008-5472.CAN-08-0969","article-title":"Opposite effects of Notch-1 and Notch-2 on mesothelioma cell survival under hypoxia are exerted through the Akt pathway","volume":"68","author":"Graziani","year":"2008","journal-title":"Cancer Res"},{"key":"B99","doi-asserted-by":"publisher","first-page":"5124","DOI":"10.1038\/onc.2008.226","article-title":"Rational targeting of Notch signaling in cancer","volume":"27","author":"Rizzo","year":"2008","journal-title":"Oncogene"},{"key":"B100","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3389\/fonc.2016.00094","article-title":"Notch signaling in neuroendocrine tumors","volume":"6","author":"Crabtree","year":"2016","journal-title":"Front Oncol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.pharmthera.2013.02.003","article-title":"Notch inhibitors for cancer treatment","volume":"139","author":"Espinoza","year":"2013","journal-title":"Pharmacol Ther"},{"key":"B102","doi-asserted-by":"publisher","first-page":"29804","DOI":"10.18632\/oncotarget.7772","article-title":"Notch signaling: its roles and therapeutic potential in hematological malignancies","volume":"7","author":"Gu","year":"2016","journal-title":"Oncotarget"},{"key":"B103","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.15252\/embr.201438842","article-title":"Pleiotropic roles of Notch signaling in normal, malignant, and developmental hematopoiesis in the human","volume":"15","author":"Kushwah","year":"2014","journal-title":"EMBO Rep"},{"key":"B104","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/ng1099","article-title":"Notch1 functions as a tumor suppressor in mouse skin","volume":"33","author":"Nicolas","year":"2003","journal-title":"Nat Genet"},{"key":"B105","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/nrc.2016.145","article-title":"Notch as a tumour suppressor","volume":"17","author":"Nowell","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"B106","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.cell.2009.03.045","article-title":"The canonical Notch signaling pathway: unfolding the activation mechanism","volume":"137","author":"Kopan","year":"2009","journal-title":"Cell"},{"key":"B107","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1242\/jcs.035683","article-title":"The molecular logic of Notch signaling \u2013 a structural and biochemical perspective","volume":"121","author":"Gordon","year":"2008","journal-title":"J Cell Sci"},{"key":"B108","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1152\/physrev.00005.2017","article-title":"Notch signaling in development, tissue homeostasis, and disease","volume":"97","author":"Siebel","year":"2017","journal-title":"Physiol Rev"},{"key":"B109","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1126\/science.284.5415.770","article-title":"Notch signaling: cell fate control and signal integration in development","volume":"284","author":"Artavanis-Tsakonas","year":"1999","journal-title":"Science"},{"key":"B110","doi-asserted-by":"publisher","first-page":"36801","DOI":"10.1074\/jbc.274.51.36801","article-title":"Cell surface presenilin-1 participates in the gamma-secretase-like proteolysis of Notch","volume":"274","author":"Ray","year":"1999","journal-title":"J Biol Chem"},{"key":"B111","doi-asserted-by":"publisher","first-page":"21232","DOI":"10.1074\/jbc.M301567200","article-title":"Structural requirements for assembly of the CSL.intracellular Notch1.Mastermind-like 1 transcriptional activation complex","volume":"278","author":"Nam","year":"2003","journal-title":"J Biol Chem"},{"key":"B112","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0070-2153(10)92003-6","article-title":"Canonical and non-canonical Notch ligands","volume":"92","author":"D\u2019Souza","year":"2010","journal-title":"Curr Top Dev Biol"},{"key":"B113","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3389\/fonc.2014.00345","article-title":"Non-canonical notch signaling in cancer and immunity","volume":"4","author":"Ayaz","year":"2014","journal-title":"Front Oncol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.ijbiomac.2017.01.067","article-title":"The non-canonical NOTCH1 ligand Delta-like 1 homolog (DLK1) self interacts in mammals","volume":"97","author":"Traustadottir","year":"2017","journal-title":"Int J Biol Macromol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"18178","DOI":"10.1074\/jbc.M117.790121","article-title":"Estrogen receptor beta-dependent Notch1 activation protects vascular endothelium against tumor necrosis factor alpha (TNFalpha)-induced apoptosis","volume":"292","author":"Fortini","year":"2017","journal-title":"J Biol Chem"},{"key":"B116","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1158\/1078-0432.CCR-14-0809","article-title":"Molecular pathways: translational and therapeutic implications of the Notch signaling pathway in cancer","volume":"21","author":"Previs","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B117","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/biof.1359","article-title":"Context-dependent function of ROS in the vascular endothelium: the role of the Notch pathway and shear stress","volume":"43","author":"Vieceli Dalla Sega","year":"2017","journal-title":"Biofactors"},{"key":"B118","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.2353\/ajpath.2007.061029","article-title":"Notch2 signaling induces apoptosis and inhibits human MDA-MB-231 xenograft growth","volume":"171","author":"O\u2019Neill","year":"2007","journal-title":"Am J Pathol"},{"key":"B119","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1006\/bbrc.2002.6528","article-title":"Functional diversity among Notch1, Notch2, and Notch3 receptors","volume":"291","author":"Shimizu","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"B120","doi-asserted-by":"publisher","first-page":"53839","DOI":"10.18632\/oncotarget.17809","article-title":"The role of Notch signaling in gastric carcinoma: molecular pathogenesis and novel therapeutic targets","volume":"8","author":"Yao","year":"2017","journal-title":"Oncotarget"},{"key":"B121","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ctrv.2017.04.003","article-title":"The Notch-1 receptor in prostate tumorigenesis","volume":"56","author":"O\u2019Brien","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"B122","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1146\/annurev-pathol-052016-100127","article-title":"The varied roles of Notch in cancer","volume":"12","author":"Aster","year":"2017","journal-title":"Annu Rev Pathol"},{"key":"B123","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.gde.2009.04.005","article-title":"Endocytic regulation of Notch signaling","volume":"19","author":"Fortini","year":"2009","journal-title":"Curr Opin Genet Dev"},{"key":"B124","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/978-3-540-74264-7_14","article-title":"SV40 and Notch-I: multi-functionality meets pleiotropy","volume":"36","author":"Carbone","year":"2004","journal-title":"Prog Mol Subcell Biol"},{"key":"B125","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/sj.onc.1206097","article-title":"Notch-1 induction, a novel activity of SV40 required for growth of SV40-transformed human mesothelial cells","volume":"22","author":"Bocchetta","year":"2003","journal-title":"Oncogene"},{"key":"B126","doi-asserted-by":"publisher","first-page":"10214","DOI":"10.1073\/pnas.170207097","article-title":"Human mesothelial cells are unusually susceptible to simian virus 40-mediated transformation and asbestos cocarcinogenicity","volume":"97","author":"Bocchetta","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B127","first-page":"6125","article-title":"Different susceptibility of human mesothelial cells to polyomavirus infection and malignant transformation","volume":"63","author":"Carbone","year":"2003","journal-title":"Cancer Res"},{"key":"B128","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/mc.20200","article-title":"Cross reactivity between many anti-human antibodies for their hamster homologs provide the tools to study the signal transduction pathway activated by asbestos and SV40 in the malignant mesothelioma model","volume":"45","author":"Kroczynska","year":"2006","journal-title":"Mol Carcinog"},{"key":"B129","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.ajpath.2016.11.008","article-title":"Asbestos-induced mesothelial to fibroblastic transition is modulated by the inflammasome","volume":"187","author":"Thompson","year":"2017","journal-title":"Am J Pathol"},{"key":"B130","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4103\/2394-4722.171982","article-title":"Roles of dysregulated Notch pathway and small DNA tumor viruses in cancer initiation and progression","volume":"2","author":"Clementz","year":"2016","journal-title":"J Cancer Metastasis Treat"},{"key":"B131","first-page":"8687","article-title":"Notch1 can contribute to viral-induced transformation of primary human keratinocytes","volume":"63","author":"Lathion","year":"2003","journal-title":"Cancer Res"},{"key":"B132","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1183\/16000617.0063-2016","article-title":"Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment","volume":"25","author":"Bibby","year":"2016","journal-title":"Eur Respir Rev"},{"key":"B133","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.lungcan.2013.11.026","article-title":"A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma","volume":"83","author":"Cao","year":"2014","journal-title":"Lung Cancer"},{"key":"B134","doi-asserted-by":"publisher","first-page":"120","DOI":"10.21037\/atm.2016.03.17","article-title":"Perspective on malignant pleural mesothelioma diagnosis and treatment","volume":"4","author":"Wald","year":"2016","journal-title":"Ann Transl Med"},{"key":"B135","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1097\/JTO.0b013e31826915f1","article-title":"Initial analysis of the international association for the study of lung cancer mesothelioma database","volume":"7","author":"Rusch","year":"2012","journal-title":"J Thorac Oncol"},{"key":"B136","doi-asserted-by":"publisher","first-page":"e0145039","DOI":"10.1371\/journal.pone.0145039","article-title":"Determinants of survival in malignant pleural mesothelioma: a surveillance, epidemiology, and end results (SEER) study of 14,228 patients","volume":"10","author":"Taioli","year":"2015","journal-title":"PLoS One"},{"key":"B137","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/thx.31.1.15","article-title":"Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients","volume":"31","author":"Butchart","year":"1976","journal-title":"Thorax"},{"key":"B138","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.jtcvs.2007.10.054","article-title":"Extrapleural pneumonectomy versus pleurectomy\/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients","volume":"135","author":"Flores","year":"2008","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B139","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","article-title":"Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the mesothelioma and radical surgery (MARS) randomised feasibility study","volume":"12","author":"Treasure","year":"2011","journal-title":"Lancet Oncol"},{"key":"B140","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1146\/annurev-med-041316-085813","article-title":"New concepts in the treatment of malignant pleural mesothelioma","volume":"69","author":"Wald","year":"2018","journal-title":"Annu Rev Med"},{"key":"B141","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.radonc.2006.06.002","article-title":"The role of radiation therapy in malignant pleural mesothelioma: a systematic review","volume":"80","author":"Ung","year":"2006","journal-title":"Radiother Oncol"},{"key":"B142","doi-asserted-by":"publisher","first-page":"242","DOI":"10.21037\/atm.2017.06.25","article-title":"Malignant pleural mesothelioma: adjuvant therapy with radiation therapy","volume":"5","author":"Rosenzweig","year":"2017","journal-title":"Ann Transl Med"},{"key":"B143","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S1470-2045(16)30095-X","article-title":"Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial","volume":"17","author":"Clive","year":"2016","journal-title":"Lancet Oncol"},{"key":"B144","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jare.2014.11.012","article-title":"Mesothelioma treatment: are we on target? A review","volume":"6","author":"Hiddinga","year":"2015","journal-title":"J Adv Res"},{"key":"B145","doi-asserted-by":"publisher","first-page":"S238","DOI":"10.3978\/j.issn.2072-1439.2014.05.03","article-title":"Management of malignant pleural mesothelioma-the European experience","volume":"6","author":"Opitz","year":"2014","journal-title":"J Thorac Dis"},{"key":"B146","doi-asserted-by":"publisher","first-page":"e532","DOI":"10.1016\/S1470-2045(17)30459-X","article-title":"Radiotherapy for the treatment of malignant pleural mesothelioma","volume":"18","author":"Perrot","year":"2017","journal-title":"Lancet Oncol"},{"key":"B147","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1016\/S1470-2045(15)00208-9","article-title":"Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17\/04): a randomised, international, multicentre phase 2 trial","volume":"16","author":"Stahel","year":"2015","journal-title":"Lancet Oncol"},{"key":"B148","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s10147-015-0925-1","article-title":"Trimodality strategy for treating malignant pleural mesothelioma: results of a feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation (Japan Mesothelioma Interest Group 0601 Trial)","volume":"21","author":"Hasegawa","year":"2016","journal-title":"Int J Clin Oncol"},{"key":"B149","doi-asserted-by":"publisher","first-page":"508","DOI":"10.3978\/j.issn.2225-319X.2012.10.05","article-title":"Chemotherapy for malignant pleural mesothelioma: a review of current management and a look to the future","volume":"1","author":"Nowak","year":"2012","journal-title":"Ann Cardiothorac Surg"},{"key":"B150","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3816\/CLC.2003.n.023","article-title":"Chemotherapy for malignant pleural mesothelioma","volume":"5","author":"Janne","year":"2003","journal-title":"Clin Lung Cancer"},{"key":"B151","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.1016\/j.lungcan.2004.04.020","article-title":"Chemotherapy for malignant pleural mesothelioma: past results and recent developments","volume":"45","author":"Tomek","year":"2004","journal-title":"Lung Cancer"},{"key":"B152","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1097\/JTO.0b013e31824cc66c","article-title":"Randomized phase 2b study of pralatrexate versus erlotinib in patients with stage IIIB\/IV non-small-cell lung cancer (NSCLC) after failure of prior platinum-based therapy","volume":"7","author":"Kelly","year":"2012","journal-title":"J Thorac Oncol"},{"key":"B153","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"B154","doi-asserted-by":"publisher","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","article-title":"Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada","volume":"23","author":"van Meerbeeck","year":"2005","journal-title":"J Clin Oncol"},{"key":"B155","first-page":"2493","article-title":"Randomized trials of systemic medically-treated malignant mesothelioma: a systematic review","volume":"35","author":"Blomberg","year":"2015","journal-title":"Anticancer Res"},{"key":"B156","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1200\/JCO.1998.16.1.145","article-title":"Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience","volume":"16","author":"Curran","year":"1998","journal-title":"J Clin Oncol"},{"key":"B157","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s11864-011-0152-6","article-title":"Chemotherapy for malignant pleural mesothelioma","volume":"12","author":"Garland","year":"2011","journal-title":"Curr Treat Options Oncol"},{"key":"B158","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.jtho.2017.05.021","article-title":"Phase I trial of cediranib in combination with cisplatin and pemetrexed in chemonaive patients with unresectable malignant pleural mesothelioma (SWOG S0905)","volume":"12","author":"Tsao","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B159","doi-asserted-by":"publisher","first-page":"ii1","DOI":"10.1136\/thx.2007.087619","article-title":"BTS statement on malignant mesothelioma in the UK, 2007","volume":"62","year":"2007","journal-title":"Thorax"},{"key":"B160","doi-asserted-by":"publisher","first-page":"v31","DOI":"10.1093\/annonc\/mdv199","article-title":"Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Baas","year":"2015","journal-title":"Ann Oncol"},{"key":"B161","doi-asserted-by":"publisher","first-page":"825","DOI":"10.6004\/jnccn.2016.0087","article-title":"NCCN guidelines insights: malignant pleural mesothelioma, version 3.2016","volume":"14","author":"Ettinger","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"key":"B162","first-page":"70","article-title":"Mesothelioma: a review","volume":"12","author":"Mott","year":"2012","journal-title":"Ochsner J"},{"key":"B163","first-page":"513","article-title":"[Clinical pathological diagnosis, and treatment for pleural mesothelioma]","volume":"43","author":"Kishimoto","year":"2016","journal-title":"Gan To Kagaku Ryoho"},{"key":"B164","doi-asserted-by":"publisher","first-page":"CD012605","DOI":"10.1002\/14651858.CD012605.pub2","article-title":"Radical multimodality therapy for malignant pleural mesothelioma","volume":"1","author":"Abdel-Rahman","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"B165","doi-asserted-by":"publisher","first-page":"325","DOI":"10.21037\/tlcr.2017.06.03","article-title":"Radio-immunotherapy and chemo-immunotherapy as a novel treatment paradigm in malignant pleural mesothelioma","volume":"6","author":"Wu","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"B166","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2147\/OV.S66091","article-title":"Oncolytic virotherapy for human malignant mesothelioma: recent advances","volume":"4","author":"Boisgerault","year":"2015","journal-title":"Oncolytic Virother"},{"key":"B167","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1080\/14737140.2017.1358091","article-title":"Immunotherapy advances for mesothelioma treatment","volume":"17","author":"Bakker","year":"2017","journal-title":"Expert Rev Anticanc"},{"key":"B168","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol"},{"key":"B169","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"key":"B170","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.trsl.2017.04.004","article-title":"CAR T-cell therapy for lung cancer and malignant pleural mesothelioma","volume":"187","author":"Zeltsman","year":"2017","journal-title":"Transl Res"},{"key":"B171","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.canlet.2017.02.015","article-title":"Intracavitary \u2018T4 immunotherapy\u2019 of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells","volume":"393","author":"Klampatsa","year":"2017","journal-title":"Cancer Lett"},{"key":"B172","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1080\/13543784.2017.1351545","article-title":"Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma","volume":"26","author":"Guazzelli","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"B173","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"B174","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.1158\/0008-5472.CAN-15-1796","article-title":"Inhibition of PAI-1 limits tumor angiogenesis regardless of angiogenic stimuli in malignant pleural mesothelioma","volume":"76","author":"Takayama","year":"2016","journal-title":"Cancer Res"},{"key":"B175","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1186\/s12967-014-0301-3","article-title":"Evaluation of clonal origin of malignant mesothelioma","volume":"12","author":"Comertpay","year":"2014","journal-title":"J Transl Med"},{"key":"B176","first-page":"60","article-title":"[Drug carrier nanosystems in malignant pleural mesothelioma]","volume":"64","author":"Turgut Cosan","year":"2016","journal-title":"Tuberk Toraks"},{"key":"B177","doi-asserted-by":"publisher","first-page":"46537","DOI":"10.1038\/srep46537","article-title":"Clinical-pharmacogenetic models for personalized cancer treatment: application to malignant mesothelioma","volume":"7","author":"Goricar","year":"2017","journal-title":"Sci Rep"},{"key":"B178","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.bbcan.2014.10.001","article-title":"Liquid biopsies in lung cancer: the new ambrosia of researchers","volume":"1846","author":"Rolfo","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"B179","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1056\/NEJMoa051185","article-title":"Asbestos exposure, pleural mesothelioma, and serum osteopontin levels","volume":"353","author":"Pass","year":"2005","journal-title":"N Engl J Med"},{"key":"B180","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1115050","article-title":"Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma","volume":"367","author":"Pass","year":"2012","journal-title":"N Engl J Med"},{"key":"B181","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1136\/thoraxjnl-2014-205205","article-title":"Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma","volume":"69","author":"Creaney","year":"2014","journal-title":"Thorax"},{"key":"B182","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s13665-015-0106-8","article-title":"Discovery of new biomarkers for malignant mesothelioma","volume":"4","author":"Creaney","year":"2015","journal-title":"Curr Pulmonol Rep"},{"key":"B183","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.jtho.2016.02.006","article-title":"Plasma biomarker enrichment of clinical prognostic indices in malignant pleural mesothelioma","volume":"11","author":"Pass","year":"2016","journal-title":"J Thorac Oncol"},{"key":"B184","doi-asserted-by":"publisher","first-page":"37502","DOI":"10.18632\/oncotarget.16398","article-title":"Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma","volume":"8","author":"Mairinger","year":"2017","journal-title":"Oncotarget"},{"key":"B185","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ejca.2007.08.028","article-title":"Mesothelin targeted cancer immunotherapy","volume":"44","author":"Hassan","year":"2008","journal-title":"Eur J Cancer"},{"key":"B186","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/S0140-6736(03)14794-0","article-title":"Mesothelin-family proteins and diagnosis of mesothelioma","volume":"362","author":"Robinson","year":"2003","journal-title":"Lancet"},{"key":"B187","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1164\/rccm.200511-1789OC","article-title":"Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma","volume":"173","author":"Scherpereel","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"B188","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.athoracsur.2007.07.042","article-title":"Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions","volume":"85","author":"Pass","year":"2008","journal-title":"Ann Thorac Surg"},{"key":"B189","doi-asserted-by":"publisher","first-page":"53751","DOI":"10.18632\/oncotarget.17910","article-title":"Biomarkers for early diagnosis of malignant mesothelioma: do we need another moonshot?","volume":"8","author":"Lagniau","year":"2017","journal-title":"Oncotarget"},{"key":"B190","doi-asserted-by":"publisher","first-page":"1725354","DOI":"10.1155\/2017\/1725354","article-title":"Plasma fibulin-3 as a potential biomarker for patients with asbestos-related diseases in the Han population","volume":"2017","author":"Jiang","year":"2017","journal-title":"Dis Markers"},{"key":"B191","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1158\/1078-0432.CCR-06-2144","article-title":"Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment","volume":"13","author":"Grigoriu","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B192","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.humimm.2012.02.009","article-title":"Specific antibodies reacting with simian virus 40 capsid protein mimotopes in serum samples from healthy blood donors","volume":"73","author":"Corallini","year":"2012","journal-title":"Hum Immunol"},{"key":"B193","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s10072-010-0353-y","article-title":"Investigation of the prevalence of antibodies against neurotropic polyomaviruses BK, JC and SV40 in sera from patients affected by multiple sclerosis","volume":"31","author":"Ribeiro","year":"2010","journal-title":"Neurol Sci"},{"key":"B194","doi-asserted-by":"publisher","first-page":"e0145720","DOI":"10.1371\/journal.pone.0145720","article-title":"Specific antibodies reacting with SV40 large T antigen mimotopes in serum samples of healthy subjects","volume":"11","author":"Tognon","year":"2016","journal-title":"PLoS One"},{"key":"B195","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1756-8722-3-37","article-title":"The clinical potential of microRNAs","volume":"3","author":"Budhu","year":"2010","journal-title":"J Hematol Oncol"},{"key":"B196","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.3978\/j.issn.2072-1439.2015.04.56","article-title":"MicroRNAs in mesothelioma: from tumour suppressors and biomarkers to therapeutic targets","volume":"7","author":"Reid","year":"2015","journal-title":"J Thorac Dis"},{"key":"B197","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.3390\/jcm4111951","article-title":"MicroRNA-34a as a therapeutic agent against human cancer","volume":"4","author":"Saito","year":"2015","journal-title":"J Clin Med"},{"key":"B198","doi-asserted-by":"publisher","first-page":"214","DOI":"10.3389\/fgene.2013.00214","article-title":"Cardiovascular extracellular microRNAs: emerging diagnostic markers and mechanisms of cell-to-cell RNA communication","volume":"4","author":"Kinet","year":"2013","journal-title":"Front Genet"},{"key":"B199","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/ncb1596","article-title":"Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells","volume":"9","author":"Valadi","year":"2007","journal-title":"Nat Cell Biol"},{"key":"B200","first-page":"200","article-title":"Comprehensive molecular oncogenomic profiling and miRNA analysis of prostate cancer","volume":"5","author":"Sethi","year":"2013","journal-title":"Am J Transl Res"},{"key":"B201","doi-asserted-by":"publisher","first-page":"135","DOI":"10.4149\/neo_2013_018","article-title":"Circulating microRNAs (cmiRNAs) as novel potential biomarkers for hepatocellular carcinoma","volume":"60","author":"Qi","year":"2013","journal-title":"Neoplasma"},{"key":"B202","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1073\/pnas.0510565103","article-title":"A microRNA expression signature of human solid tumors defines cancer gene targets","volume":"103","author":"Volinia","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B203","doi-asserted-by":"publisher","first-page":"58606","DOI":"10.18632\/oncotarget.9686","article-title":"Diagnostic value of microRNAs in asbestos exposure and malignant mesothelioma: systematic review and qualitative meta-analysis","volume":"7","author":"Micolucci","year":"2016","journal-title":"Oncotarget"},{"key":"B204","doi-asserted-by":"publisher","first-page":"R157","DOI":"10.1530\/ERC-16-0525","article-title":"MicroRNA applications for prostate, ovarian and breast cancer in the era of precision medicine","volume":"24","author":"Smith","year":"2017","journal-title":"Endocr Relat Cancer"},{"key":"B205","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ebiom.2016.09.017","article-title":"MicroRNA therapeutics in cancer \u2013 an emerging concept","volume":"12","author":"Shah","year":"2016","journal-title":"EBioMedicine"},{"key":"B206","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1164\/rccm.201503-0461LE","article-title":"A significant metabolic and radiological response after a novel targeted microRNA-based treatment approach in malignant pleural mesothelioma","volume":"191","author":"Kao","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"B207","doi-asserted-by":"publisher","first-page":"7672","DOI":"10.1158\/0008-5472.CAN-09-1843","article-title":"Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties","volume":"69","author":"Luistro","year":"2009","journal-title":"Cancer Res"},{"key":"B208","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-09-2823","article-title":"Targeting Notch to target cancer stem cells","volume":"16","author":"Pannuti","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B209","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/2045-824X-4-7","article-title":"Notch signals in the endothelium and cancer \u201cstem-like\u201d cells: opportunities for cancer therapy","volume":"4","author":"Gu","year":"2012","journal-title":"Vasc Cell"},{"key":"B210","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nrclinonc.2015.61","article-title":"Targeting Notch, hedgehog, and Wnt pathways in cancer stem cells: clinical update","volume":"12","author":"Takebe","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"B211","doi-asserted-by":"publisher","first-page":"27985","DOI":"10.1038\/srep27985","article-title":"A humanized anti-DLL4 antibody promotes dysfunctional angiogenesis and inhibits breast tumor growth","volume":"6","author":"Jia","year":"2016","journal-title":"Sci Rep"},{"key":"B212","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3389\/fonc.2014.00254","article-title":"The notch ligand JAGGED1 as a target for anti-tumor therapy","volume":"4","author":"Li","year":"2014","journal-title":"Front Oncol"},{"key":"B213","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13287-017-0573-7","article-title":"The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells","volume":"8","author":"Pattarozzi","year":"2017","journal-title":"Stem Cell Res Ther"},{"key":"B214","first-page":"4239","article-title":"Targeting the Wnt signaling pathway with dishevelled and cisplatin synergistically suppresses mesothelioma cell growth","volume":"27","author":"Uematsu","year":"2007","journal-title":"Anticancer Res"},{"key":"B215","doi-asserted-by":"publisher","first-page":"335","DOI":"10.21037\/tlcr.2017.06.02","article-title":"Drug development against the hippo pathway in mesothelioma","volume":"6","author":"Woodard","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"B216","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1007\/s00018-010-0391-x","article-title":"Non-canonical activation of Notch signaling\/target genes in vertebrates","volume":"67","author":"Sanalkumar","year":"2010","journal-title":"Cell Mol Life Sci"},{"key":"B217","doi-asserted-by":"publisher","first-page":"16074","DOI":"10.1038\/ncomms16074","article-title":"Non-canonical NOTCH3 signalling limits tumour angiogenesis","volume":"8","author":"Lin","year":"2017","journal-title":"Nat Commun"},{"key":"B218","doi-asserted-by":"publisher","first-page":"E739","DOI":"10.3390\/ijms17050739","article-title":"A tumor-specific neo-antigen caused by a frameshift mutation in BAP1 is a potential personalized biomarker in malignant peritoneal mesothelioma","volume":"17","author":"Lai","year":"2016","journal-title":"Int J Mol Sci"},{"key":"B219","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fonc.2018.00091\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T04:19:18Z","timestamp":1522729158000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fonc.2018.00091\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,3]]},"references-count":219,"alternative-id":["10.3389\/fonc.2018.00091"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2018.00091","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,3]]},"article-number":"91"}}